Lutein and zeaxanthin are the carotenoids the human macula concentrates on its own, and Japan has sold them as an eye-health ingredient for years — in soft capsules, mostly from marigold flowers. Brands abroad ask for a Japan-made lutein/zeaxanthin product because of that track record, and because the research base is genuinely large.
This guide is for brand owners planning a Japan-made lutein and zeaxanthin product. It covers what the trials measure, why AREDS2 is not a product claim, how Japanese Foods with Function Claims frame the ingredient, and what to decide before a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a lutein and zeaxanthin product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
A 2021 meta-analysis of 46 trials found that lutein/zeaxanthin intake raises macular pigment optical density in people with healthy eyes, with a larger rise at higher doses.
| Study | Design/What was analysed | Reported result |
|---|---|---|
| Systematic review and meta-analysis, Advances in Nutrition 2021, 12(6):2244–2254 (PMID 34157098, DOI 10.1093/advances/nmab071) | 46 randomised trials, 3,189 participants, mean age 43, of oral lutein/zeaxanthin and macular pigment optical density (MPOD) | MPOD increased with intake in adults with healthy eyes; pooled increase 0.04 units at 5 to under 20 mg/day, 0.11 units at 20 mg/day or more over 3–12 months; effects below 5 mg/day or from diet alone were less clear |
| Randomised, double-masked, placebo-controlled trial, Nutrients 2017 (PMC5707718) | 51 healthy adults aged 18–30 (37 supplement, 14 placebo) given a lutein and zeaxanthin combination for one year; funded by a nutrition company | Reported changes in MPOD and in some cognitive-function measures over the intervention period |
| Randomised, double-masked, placebo-controlled trial, JAMA 2013 — AREDS2 (PMID 23644932) | 4,203 people aged 50–85 at risk of advanced age-related macular degeneration (AMD), given lutein 10 mg + zeaxanthin 2 mg, omega-3 fatty acids, both, or placebo on top of the AREDS formula; median follow-up 5 years | In the primary analyses, adding lutein/zeaxanthin to the AREDS formula did not significantly reduce progression to advanced AMD (5-year progression 29% versus 31% with placebo); the authors suggested lutein/zeaxanthin as a possible substitute for beta carotene in the formula |
Three points to keep in view:
- AREDS2 was a trial in people who already had an eye disease. Its participants were at risk of advanced AMD, not healthy volunteers, and the formula tested was a specific multi-nutrient combination, not lutein/zeaxanthin alone. It belongs in the research table as a fact about the science — never as a claim on a product label.
- The MPOD meta-analysis is in healthy eyes, and MPOD is a biomarker, not a guarantee of better vision for the person taking it. A systematic review has also reported an association between MPOD and visual-function measures such as contrast sensitivity and glare recovery, but the meta-analysis authors called for more, larger studies of visual-function outcomes directly.
- Dose matters in the data. The clearer MPOD rise was seen at 20 mg/day or more, well above what many consumer products contain.
Checked against the published abstracts on 25 September 2026.
What Japanese products say
In Japan, lutein and zeaxanthin appear in Foods with Function Claims notified for functions described as supporting contrast sensitivity (clarity of vision) and glare recovery, and for reducing everyday light stress such as from blue light.
Under Japan’s Foods with Function Claims system, the notifying business is responsible for the scientific evidence behind the stated function and submits it to the Consumer Affairs Agency before sale. Notified products in this category commonly combine lutein and zeaxanthin at amounts such as 20 mg and around 4 mg per day, referencing macular pigment and contrast-sensitivity research.
Two lessons for a brand abroad:
- The notified wording describes a visual function, not a disease outcome. It speaks of contrast sensitivity, glare recovery and light stress — not AMD, not “protects your eyesight” as a medical guarantee.
- A Japanese notification is a Japanese mechanism. It does not transfer to your own market’s rules, and the amount in a Japanese notification is not automatically the amount you should claim against abroad.
💬 Need an evidence summary for your regulatory adviser that separates the healthy-eye MPOD data from the AREDS2 disease-population trial? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe lutein/zeaxanthin by what was measured — macular pigment, contrast sensitivity, light stress — never by a disease it would prevent or treat.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied for macular pigment density in healthy eyes" | "Prevents macular degeneration”, “protects against AMD" |
| "Contains lutein and zeaxanthin” with the amount per serving | Citing AREDS2 as evidence for a general consumer product |
| ”Studied for contrast sensitivity and glare” (only if your dose matches supporting data) | “Clinically proven” without naming the study and its dose |
How lutein and zeaxanthin are formulated
Lutein and zeaxanthin are oil-soluble carotenoids, so Japanese products almost always put them in a soft capsule with an oil carrier.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Soft capsule | Oil fill suits an oil-soluble carotenoid; standard in Japan for this ingredient | Shell material (gelatin or plant-based) for dietary suitability |
| Hard capsule with oil-based bead or powder | Combines with other actives in a multi-ingredient formula | Needs a stabilised, powdered carotenoid form |
| Tablet | Possible with a stabilised powder form | Bioavailability and stability need supplier data |
Decisions that shape the specification:
- Source. Lutein and zeaxanthin used in supplements are commonly extracted from marigold (Tagetes erecta) flowers. Ask the supplier for the extraction method, the lutein-to-zeaxanthin ratio and the isomer profile.
- Amount per serving. Match the amount to the study you intend to cite — the MPOD meta-analysis shows a clearer effect at 20 mg/day or more, well above many market products.
- Companion ingredients. Bilberry extract, astaxanthin and omega-3 fatty acids are common eye-health partners in Japan. Each needs its own check against Japanese food law and your market’s rules.
- Oil carrier and stability. Carotenoids oxidise; the oil carrier, antioxidant system and packaging (light-protective blister or bottle) affect shelf life. Ask the factory for stability data at your target shelf life.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Lutein and zeaxanthin from marigold are widely used in Japanese foods. Eye-health formulas sometimes add botanical extracts that Japan treats differently from how they are treated in your home market, so the full formula needs checking before a factory can commit. See the Japan-made supplement OEM page, and our bilberry and astaxanthin guides if you are planning a combined eye-health product.
Before you ask for a quotation
A factory can quote accurately once the amount, the source, the companions and the packaging are fixed.
- Lutein and zeaxanthin amounts per serving, and their ratio
- Source and isomer specification
- Companion ingredients and their amounts
- Soft capsule shell material and packaging
- Countries you will sell in, and first order and annual volume
💬 Ready to design a Japan-made lutein and zeaxanthin product? Send us the concept — amounts, source, companion ingredients and the countries you will sell in.
Frequently asked questions
1. Does lutein/zeaxanthin supplementation help eye health?
A 2021 meta-analysis of 46 trials found that intake raises macular pigment optical density in people with healthy eyes, more so at higher doses. Direct visual-function evidence at typical consumer doses is more limited, so describe the ingredient as studied for macular pigment, not as a guaranteed vision benefit.
2. Can I use the AREDS2 results to market my product?
No. AREDS2 studied people already at risk of advanced age-related macular degeneration, using a specific multi-nutrient formula, over a median of five years. It is a fact for the research table, not a claim for a general consumer product.
3. What dose does the research use?
The clearer rise in macular pigment was seen at 20 mg/day or more of combined lutein and zeaxanthin. Match your labelled amount to the study you cite.
4. Why is lutein/zeaxanthin almost always in a soft capsule?
It is oil-soluble. A soft capsule with an oil fill suits the ingredient and is the standard Japanese format; other forms need a stabilised powder version.
5. What can stop a Japanese factory making my lutein/zeaxanthin product?
Usually a companion botanical in an eye-health blend. Every ingredient must be permitted in foods in Japan, so we check the full formula first.
Sources: “The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis”, Advances in Nutrition 2021, 12(6):2244–2254, DOI 10.1093/advances/nmab071 (PMID 34157098); “Effects of a Lutein and Zeaxanthin Intervention on Cognitive Function: A Randomized, Double-Masked, Placebo-Controlled Trial of Younger Healthy Adults”, Nutrients 2017 (PMC5707718); “Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial”, JAMA 2013 (PMID 23644932); Consumer Affairs Agency notifications for Foods with Function Claims. Checked on 25 September 2026.